OLMA

Olema Pharmaceuticals Inc. a clinical-stage biopharmaceutical company focuses on the discovery development and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250 an estrogen receptor (ER) antagonist and a selective ER degrader which is in Phase 1/2 clinical trial for the treatment of recurrent locally advanced or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib ribociclib and alpelisib in Phase 1b/2 clinical trial for the treatment of recurrent locally advanced or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera Inc. and changed its name to Olema Pharmaceuticals Inc. in March 2009. Olema Pharmaceuticals Inc. was incorporated in 2006 and is headquartered in San Francisco California.